|
|
News Breaks | | | | September 21, 2012 | | 08:00 EDT |  | ATEC, ATEC, JNJ, JNJ, SYK, SYK, NUVA, NUVA, TSON, TSON, ZMH, ZMH | FDA Orthopaedic and Rehabilitation Devices Panel to hold a meeting
The Committee discuses and make recommendations regarding the classification of posterior cervical screws, including pedicle and lateral mass screws. Companies that develop posterior cervical screw systems include Alphatec Holdings--ATEC, Johnson & Johnson--JNJ, Stryker Corp--SYK, NuVasive--NUVA, TranS1--TSON, and Zimmer Holdings--ZMH. The meeting is being held in Gaithersburg, Maryland on September 21 at 8 am. Webcast Link | |
|
News For ATEC;JNJ;SYK;NUVA;TSON;ZMH From The Last 14 Days Check below for free stories on ATEC;JNJ;SYK;NUVA;TSON;ZMH the last two weeks. |
|
|
| June 19, 2013 | | 09:56 EDT | | NUVA | NuVasive has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Alex Lukianov on June 21 at 2 pm. | | | 08:45 EDT | | JNJ | Leerink's biotech analyst holds analyst/industry conference call on ADA
Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm. | | | 07:57 EDT |  | NUVA | NuVasive named a top new money pick at Canaccord
 Subscribe for More Information | | | June 18, 2013 | | 07:34 EDT | | JNJ | Medivation pullback a buying opportunity, says JPMorgan
Subscribe for More Information | | | June 17, 2013 | | 16:20 EDT |  | JNJ | On The Fly: Closing Wrap
Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04. | | | 12:29 EDT | | JNJ | On The Fly: Midday Wrap
Subscribe for More Information | | | 12:28 EDT |  | JNJ | Medivation retreats after J&J beefs up prostate cancer slate
Subscribe for More Information | | | 12:08 EDT | | JNJ | J&J deal not negative for Medivation, says Citigroup
Subscribe for More Information | | | 08:04 EDT | | JNJ | Johnson & Johnson agrees to acquire Aragon Pharmaceuticals
Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650M, plus additional contingent payments of up to $350M based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013. | | | June 16, 2013 | | 14:45 EDT |  | JNJ | J&J's Depuy Synthes unit wins $16M in patent case, Bloomberg says
Subscribe for More Information | | | | June 14, 2013 | | 15:49 EDT | | JNJ | J&J's Mentor gets FDA approval for MemoryShape breast implants
Mentor Worldwide announced earlier the U.S. Food and Drug Administration has approved MENTOR MemoryShape breast implants. The open-label, multi-center MENTOR MemoryShape Breast Implant Core Study showed the implants were safe and effective in both reconstruction and augmentation patients at 6 years, with a low rate of adverse events, such as rupture and capsular contracture Baker grades III and IV. Post approval studies will be conducted to collect additional clinical data for the MemoryShape implants. Mentor joined the Johnson & Johnson family of companies in 2009 and is part of its Global Surgery Group. | | | June 13, 2013 | | 17:39 EDT |  | JNJ | J&J files to sell 25.38M shares of Elan
Subscribe for More Information | | | 11:02 EDT | | JNJ | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information | | | 08:24 EDT | | JNJ | J&J unit says data show Stelara improved components of psoriatic arthritis
Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that results from a Phase 3 study published in The Lancet showed patients with active psoriatic arthritis who received either STELARA 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint compared with patients receiving placebo. According to findings from the investigational study, continued treatment with STELARA every 12 weeks resulted in improvements in signs and symptoms of active disease and psoriasis symptoms through one year. In December 2012, Janssen announced submissions to health authorities in the U.S. and Europe seeking approval of STELARA for the treatment of active psoriatic arthritis. STELARA is approved for the treatment of adults with moderate to severe plaque psoriasis in 72 countries. | | | June 12, 2013 | | 17:56 EDT | | JNJ | Johnson & Johnson's Cordis receives FDA clearance for Adroit catheter
Subscribe for More Information | | | 10:20 EDT | | NUVA | NuVasive new royalty rates a modest negative, says Wells Fargo
Subscribe for More Information | | | 05:25 EDT | | NUVA | NuVasive announces court ruling, intends to appeal verdict in Medtronic case
NuVasive announced that it received a ruling from the U.S. District Court in regards to ongoing royalty rates for Phase I of its patent litigation with Medtronic. As part of the verdict in Phase I of the litigation, royalty rates were determined by the jury as follows: 10% on certain of NuVasive's CoRoent XL implants and 3% on certain MaXcess retractors and related products. Before the appeal in Phase I could move forward, the Court was required to determine the ongoing royalty rates applicable to these products during the period of time following the verdict. Medtronic requested ongoing royalty rates of 36% on the applicable NuVasive CoRoent XL implants and 11% on the applicable MaXcess retractors and related products. However, in the ruling received, the Court ordered royalty rates of 13.75% on the applicable CoRoent XL implants and 8.25% on the applicable MaXcess retractors. Since September 2011, NuVasive has been accruing an estimated litigation royalty expense based on the royalty rates used in the jury's original calculation of lost profits and monetary damages. Prior to the post-verdict rates issued by the Court, the company had expected litigation royalty expense of approximately $11M for FY13. The new royalty rates determined today will increase that expected litigation royalty expense for 2013 by approximately $5M. In addition, in the current quarter, the company will record an approximate $6.5M charge to account for the historical difference between the post-verdict royalty rates determined today and the rates that were being used to calculate the litigation royalty expense accruals since September 2011. The vast majority of the litigation royalty expense accruals will end in February 2015 as certain Medtronic patents expire. As the verdict is being appealed, the company will accrue to the higher rates determined and will begin to escrow funds on a go-forward basis. | | | June 11, 2013 | | 16:12 EDT | | ATEC | Alphatec postpones annual meeting to allow holders to review amendments
Subscribe for More Information | | | 10:56 EDT | | JNJ | AstraZeneca to bid for Israeli biotech incubator, Globes reports
Subscribe for More Information | | | June 10, 2013 | | 07:40 EDT | | JNJ | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | |
|
|
|
|
|
|
